FDA Alert Warns Of Adverse Events With Genzyme/Schering AG's Campath
This article was originally published in The Pink Sheet Daily
Executive Summary
The alert on idiopathic thrombocytopenia purpura comes nearly three months after the companies halted dosing in a multiple sclerosis trial of alemtuzumab due to ITP events.
You may also be interested in...
Genzyme’s Campath MS Safety Profile Expected From FDA By July; Phase III Set For Second Half
The firm expects to re-start a Phase II trial of alemtusumab in multiple sclerosis patients that was halted in 2005.
Genzyme’s Campath MS Safety Profile Expected From FDA By July; Phase III Set For Second Half
The firm expects to re-start a Phase II trial of alemtusumab in multiple sclerosis patients that was halted in 2005.
Campath Could Be Approved For Multiple Sclerosis By 2009, Genzyme Says
Genzyme CEO Termeer predicts the approval process will take three to four years following the halting of a Phase II trial in MS because of safety concerns.